diaDexus (DDXS.OB), based in South San Francisco, California, develops and commercializes proprietary diagnostic products addressing unmet needs in cardiovascular disease (CVD). diaDexus has two tests cleared by the FDA:
· The PLAC® Test ELISA Kit is a Lp-PLA2 blood test to aid in predicting risk for both coronary heart disease and ischemic stroke associated with atherosclerosis.
· The PLAC® Test for Lp-PLA2 Activity is to be used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk of coronary heart disease (CHD) in patients with no prior history of cardiovascular events, which represents approximately 75% of coronary heart disease patients.
The Company also has biomarkers for heart failure, with the first marker to enter development by year-end 2014.
View all » Recent Releases